Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 11854 pages

Showing 101 - 150


2020 Class of Giants of Cancer Care Announced

The Eighth Annual Giants of Cancer Care class of inductees was recently announced by OncLive, a multimedia resource focused on providing oncology professionals with relevant information on patient care. The virtual awards ceremony will be held on November 5 at 7.30 PM EST and will be available...

issues in oncology
colorectal cancer

Study Finds Racial Disparities in Management of Colorectal Cancer Spreading to the Liver

Colorectal cancer is more prevalent among Black people, a group with the highest rates of death for an illness that is curable if caught early. “The unfortunate reality is that minorities, especially Black people, have a much lower chance of getting life-saving cancer treatment. Health care works...

solid tumors
head and neck cancer

Neck Tumor

The text and photographs here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...

University of Rochester School of Medicine and Dentistry Names Ruth O’Regan, MD, Chair, Department of Medicine

Ruth O’Regan, MD, Chief of Hematology, Medical Oncology and Palliative Care at the University of Wisconsin, has been named the next Charles A. Dewey Professor and Chair of Medicine at the University of Rochester Medical Center’s (URMC) School of Medicine and Dentistry, pending approval by the...

Cedars-Sinai Announces Addition of New Researchers, Physicians to Faculty

In a news release issued earlier this month, Dan Theodorescu, MD, PhD, Director of Cedars-Sinai Cancer Center in Los Angeles, welcomed several new researchers and physicians to the faculty of the institution. “I am very grateful to the institutional leadership that our efforts to expand the breadth ...

covid-19

A Young Oncologist Cares for Patients With Cancer Amid COVID-19 Pandemic

The COVID-19 pandemic changed the face of U.S. health-care services in such rapid fashion that many providers were caught off guard, learning and preparing on the fly. Patients with cancer, given their multiple physical and emotional challenges, were especially vulnerable. To get a sense of the...

breast cancer

Phase III NALA Trial Meets Primary Endpoint in Previously Treated HER2-Positive Breast Cancer

As reported in the Journal of Clinical Oncology by Cristina Saura, MD, of Vall d’Hebron University Hospital, Barcelona, and colleagues, the phase III NALA trial has shown significantly prolonged progression-free survival with the irreversible pan-HER tyrosine kinase inhibitor neratinib plus...

immunotherapy

City of Hope Scientists Explore Combination Immunotherapy for Solid Tumors

City of Hope scientists have combined two immunotherapies—an oncolytic virus and chimeric antigen receptor (CAR) T-cell therapy—to target solid tumors that are otherwise difficult to treat with CAR T-cell therapy alone, according to a recent study in Science Translational Medicine.1 In preclinical...

breast cancer

Tucatinib Combination Extends Survival in HER2-Positive Metastatic Breast Cancer, Including Patients With Brain Metastases

For patients with progressing HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1), no single regimen is an established standard of care. More than 50% of these patients will develop brain metastasis, and thus far, treatments...

Wesley Family Donates $10 Million to Seidman Cancer Center

In honor of a transformational $10 million gift from Kimberly and Joseph Wesley, University Hospitals is establishing the Wesley Center for Immunotherapy at University Hospitals (UH) Seidman Cancer Center in Cleveland. This gift will further enable physician-scientists to engage in groundbreaking...

Deirdre J. Cohen, MD, MS, Appointed Director of Mount Sinai Health System’s GI Oncology Program

Deirdre J. Cohen, MD, MS, an expert in pancreatic and other gastrointestinal cancers as well as an accomplished clinical trial leader, has joined Mount Sinai Health System as Director of the Gastrointestinal (GI) Oncology Program and Medical Director of the Cancer Clinical Trials Office at The...

breast cancer

Managing Breast Cancer in a Pregnant Patient

“One of themost challenging oncologic situations is the diagnosis of breast cancer in a young pregnant patient,” Jacqueline Jeruss, MD, PhD, Associate Dean, Regulatory Affairs; Director of the Breast Care Center; and Professor of Surgery, Pathology, and Biomedical Engineering at the University of...

breast cancer

High-Risk, HER2-Positive Breast Cancer: Neoadjuvant and Adjuvant Treatment Options

Although most patients with breast cancer are considered to have an overall excellent prognosis, 600,000 people still die annually of the disease around the world. Even in HER2-positive breast cancer, a subtype that has seen a transformation of outcomes in the past 2 decades, there’s still room for ...

breast cancer

HER2-Positive Metastatic Breast Cancer Highlights 2019–2020 Almanac

The past 2 years have seen a dramatic change in the standard of care for patients with HER2-positive metastatic breast cancer whose disease has progressed on trastuzumab. Promising new agents and combinations for later lines of therapy may also challenge current treatment strategies, according to...

Cancer in Older Adults: The History of Geriatric Oncology, 1980–2015

The development of geriatric oncology has been slow but progressive. Thanks to the effort of investigators throughout the world, embattled but undeterred by the objection of a cautious establishment, geriatric oncology has provided a blueprint for the treatment of cancer in the population of...

Dana-Farber Researcher Receives Victoria Mock New Investigator Award

Robert Knoerl, PhD, RN, Instructor in Medicine and Nurse-Scientist at the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute, has been awarded the 2020 Oncology Nursing Society’s Victoria Mock New Investigator Award. This prestigious award is ...

integrative oncology

Astragalus

The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien Hou, PharmD, DipIOM, LAc, and Jyothirmai Gubili, MS, focus on the...

covid-19

Cancer Centers Nationwide Join to Address the Impact of COVID-19 on Cancer Prevention and Treatment

A consortium of 17 cancer centers in the United States, including the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham (UAB), have come together to better understand the consequences of the COVID-19 pandemic in delaying cancer detection, care, and prevention. The cancer ...

multiple myeloma

Red Flag Presentations of Immunoglobulin Light Chain Amyloidosis in Patients With Multiple Myeloma

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, the authors highlight the most common type of systemic amyloidosis in the United States: immunoglobulin light chain [or amyloid light...

Emmanuelle Charpentier, PhD, and Jennifer A. Doudna, PhD, Honored With Nobel Prize in Chemistry 2020

On October 7, 2020, The Royal Swedish Academy of Sciences announced that the Nobel Prize in Chemistry 2020 would be awarded to Emmanuelle Charpentier, PhD, and Jennifer A. Doudna, PhD, “for the development of a method for genome editing,” the CRISPR/Cas9 genetic scissors. “There is enormous power...

breast cancer

Long-Term Evaluation of Treatment Efficacy After Primary DCIS Diagnosis

A long-term study of women with ductal carcinoma in situ (DCIS) has shown that surgery to remove the tissue followed by radiotherapy may lower the risk of subsequent cancer compared to surgery alone. The study, presented at the 12th European Breast Cancer Conference by van Seijen et al (Abstract...

genomics/genetics

Cancer Therapy Based on Molecular Tumor Board Recommendations: Improvement in Outcomes?

Patients receiving care for advanced cancer based on the recommendations of a molecular tumor board were more likely to survive or experience a longer period without disease progression, according to results from a study published by Kato et al in Nature Communications. Razelle Kurzrock, MD,...

breast cancer

Breast Cancer Risk After Benign Breast Disease

Benign breast disease is known to increase the chances of subsequent breast cancer. According to Spanish researchers, the way benign breast disease is detected may be an indication of how likely it is to become cancerous. The findings from the team led by Xavier Castells, MD, PhD, Head of the...

gynecologic cancers

Andreas du Bois, MD, PhD, on Ovarian Cancer: Niraparib, Trabectedin Plus Doxorubicin, Platinum, and Carboplatin

Andreas du Bois, MD, PhD, of Kliniken Essen Mitte, discusses the NORA and INOVATYON studies of patients with recurrent ovarian cancer, detailing the findings for women in China with platinum-sensitive disease and women internationally who received trabectedin and pegylated liposomal doxorubicin...

issues in oncology
covid-19

CancerLinQ Data Reveal Black and Hispanic Patients With Cancer Face Greater Risk of COVID-19 Infection

Black and Hispanic patients with cancer were more likely to be infected with COVID-19 than White patients, based on the findings of a study of more than 477,000 patients to be presented by Potter et al at the upcoming virtual 2020 ASCO Quality Care Symposium (Abstract 84). About the Study...

issues in oncology
covid-19

Black Patients With Cancer May Be at Increased Risk for Hospitalization Related to COVID-19 Infection

A study of more than 500 patients with cancer infected with COVID-19 at a large cancer center in Boston found that Black patients with cancer and COVID-19 were twice as likely to be hospitalized due to complications related to the virus as compared to White patients. Black patients were also more...

issues in oncology
covid-19

Study Finds Black and Hispanic Patients With Cancer Used Telehealth Less Often Than White Patients During the COVID-19 Pandemic

During the peak of the COVID-19 pandemic, fewer Black and Hispanic patients with cancer used telehealth (including phone encounters and video visits) compared to White patients, according to findings from an analysis of data from New York City hospitals. Significant disparities in the use of...

breast cancer

Novel Indications and New Drugs for the Treatment of Patients With Breast Cancer

Over the past year (December 2019–September 2020), the U.S. Food and Drug Administration (FDA) granted approval to several novel drugs and new indications for therapeutic agents used in breast cancer. Pertuzumab/Trastuzumab/Hyaluronidase-zzxf On June 29, 2020, the FDA approved a new fixed-dose...

breast cancer

Emerging Alternatives in the Third-Line Setting for Metastatic HER2-Positive Breast Cancer

In the post-trastuzumab era, a number of U.S. Food and Drug Administration (FDA)-approved targeted agents for metastatic HER2-positive breast cancer are available, but there is no preferred option for third-line treatment and beyond. At the 2019 Chemotherapy Foundation Symposium, Shanu Modi, MD,...

breast cancer

Tucatinib Combination in Previously Treated HER2-Positive Metastatic Breast Cancer With Brain Metastases

In an analysis of the pivotal phase III HER2CLIMB trial reported at the ASCO20 Virtual Scientific Program, Nancy U. Lin, MD, of Dana-Farber Cancer Institute, Boston, and colleagues found that tucatinib, a small-molecule tyrosine kinase inhibitor that is highly selective for HER2, plus...

breast cancer

Local Recurrence With Radiation Boost in HER2-Positive Breast Cancer: HERA Trial Analysis

In a retrospective analysis reported in the International Journal of Radiation Oncology • Biology • Physics, Joseph Abi Jaoude, MD, of the American University of Beirut Medical Center, and colleagues found that a radiation boost did not reduce the risk of local recurrence among women with...

breast cancer

Advanced HER2-Positive Breast Cancer: All Eyes on These Novel Agents

New agents for the treatment of advanced HER2-positive breast cancer should be coming soon to your clinic, according to Sara A. Hurvitz, MD, Director of the Breast Cancer Clinical Research Program and Associate Professor of Medicine at the David Geffen School of Medicine at the University of...

breast cancer

Updates From Additional Clinical Trials in HER2-Positive Breast Cancer

Here we present summaries of several additional clinical trials in HER2-positive breast cancer reported over the past year. Jame Abraham, MD, Chair of the Division of Hematology and Oncology at the Taussig Cancer Center, Cleveland Clinic, shared his perspective on several of these trials presented ...

Expert Point of View: Ian E. Krop, MD, PhD, Angela M. DeMichele, MD, MSCE, and Carlos L. Arteaga, MD

Ian E. Krop, MD, PhD, of Dana-Farber Cancer Institute, Boston, said that margetuximab is one of three new “exciting” drugs in the HER2-positive setting with different mechanisms of action; the other two are tucatinib and trastuzumab deruxtecan. “Margetuximab is a modified version of trastuzumab...

breast cancer

Phase III SOPHIA Trial Evaluates Margetuximab/Chemotherapy vs Trastuzumab/Chemotherapy for HER2-Positive Breast Cancer

The second interim analysis of the phase III SOPHIA trial demonstrated a significant, though modest, improvement in progression-free survival, response rate, and clinical benefit with the addition of margetuximab to chemotherapy vs trastuzumab plus chemotherapy in patients with HER2-positive...

breast cancer

Abemaciclib/Fulvestrant/Trastuzumab for Patients With Previously Treated HR-Positive, HER2-Positive Advanced Breast Cancer

In the phase II monarcHER trial reported in The Lancet Oncology, Sara M. Tolaney, MD, of Dana-Farber Cancer Institute, Boston, and colleagues, found that the combination of abemaciclib, fulvestrant, and trastuzumab prolonged progression-free survival vs trastuzumab plus standard-of-care...

hepatobiliary cancer

2020 Nobel Prize in Physiology or Medicine Awarded to Team Who Discovered Hepatitis C Virus

This year’s Nobel Prize in Physiology or Medicine was awarded to three scientists who have made a decisive contribution to the fight against blood-borne hepatitis, a major global health problem that causes cirrhosis and liver cancer in people around the world. Harvey J. Alter, MD; Michael Houghton, ...

genomics/genetics

Pilot Study Finds Liquid Biopsy Delivers Results Faster Than Tissue Biopsy

A pilot study comparing liquid biopsy with tissue-based testing showed that liquid biopsy delivered results approximately 10 days faster than tissue biopsy, according to research presented by Nir Peled, MD, PhD, and colleagues at the International Association for the Study of Lung Cancer (IASLC)...

lung cancer
genomics/genetics

Liquid Biopsy May Be a Timely and Effective Testing Method for Patients With NSCLC: Findings From Canada

Next-generation sequencing of cell-free DNA (cfDNA) obtained from blood samples may improve diagnostic testing in patients with advanced non–small cell lung cancer (NSCLC) and may also be faster and less expensive than standard tissue profiling, according to research presented by Natasha B. Leighl, ...

lung cancer
immunotherapy

FDA Approves Nivolumab Plus Ipilimumab for the First-Line Treatment of Unresectable Malignant Pleural Mesothelioma

On October 2, the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) as first-line treatment for adult patients with unresectable malignant pleural mesothelioma. CheckMate 743 Efficacy was investigated in CheckMate 743, a randomized,...

skin cancer
immunotherapy

Jeffrey S. Weber, MD, PhD, on Melanoma: Adjuvant Nivolumab vs Ipilimumab

Jeffrey S. Weber, MD, PhD, of the Perlmutter Cancer Center, NYU Langone, discusses the 4-year recurrence-free and overall survival results from the CheckMate 238 study, which showed adjuvant nivolumab continues to be an effective treatment, vs the comparator ipilimumab, for patients with resected...

immunotherapy
multiple myeloma
lymphoma
gastroesophageal cancer
gastrointestinal cancer
breast cancer

FDA Pipeline: Priority Review for Agents in Multiple Myeloma, Anaplastic Large Cell Lymphoma

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to therapies for pretreated patients with multiple myeloma and pediatric patients with ALK-positive anaplastic large cell lymphoma; granted Fast Track designation to novel agents in gastric/gastroesophageal junction...

issues in oncology

Is Cancer Mortality Higher in Counties That Experience Persistent Poverty?

Residents of counties that experience persistent poverty face a disproportionately high risk of cancer mortality, according to a study published by Jennifer L. Moss, PhD, and colleagues in Cancer Epidemiology, Biomarkers & Prevention. Persistent Poverty Areas of persistent poverty are defined...

issues in oncology

Ending Systemic Racism in Oncology Is Everyone’s Responsibility

Five years ago, as Rachel B. Issaka, MD, MAS, was beginning her second year as a gastroenterology fellow and feeling proud of the progress she was making in her training, she was suddenly confronted with an all-too-familiar slight that underrepresented minority providers may often experience. As...

gastrointestinal cancer
genomics/genetics

Genetic Testing May Be Cost-Effective for Newly Diagnosed Patients With GIST

In a paper published by Banerjee et al in JAMA Network Open, researchers reported that genetic testing is cost-effective and beneficial for newly diagnosed patients with metastatic gastrointestinal stromal tumors (GIST), a type of soft-tissue sarcoma that develops in specialized nerve cells in the...

issues in oncology

An MSK Hospitalist Looks at Oncologists’ Attitudes About Inpatient Cancer Care

Each year in the United States, about five million adults with cancer are admitted to hospitals. Given our aging population, this trend will increase, putting added stress on the oncology community, which is already dealing with an impending workforce shortage. Although physician extenders, such...

breast cancer
symptom management

Monika K. Krzyzanowska, MD, MPH, on Early-Stage Breast Cancer: Ambulatory Toxicity Management in the AToM Study

Monika K. Krzyzanowska, MD, MPH, of the Princess Margaret University Health Network, discusses study findings on remote proactive telephone-based toxicity management for patients with breast cancer receiving chemotherapy. Although the telehealth program was associated with fewer grade 3 toxicities...

breast cancer
immunotherapy

Lisa A. Carey, MD, on Triple-Negative Breast Cancer: Paclitaxel, Nab-paclitaxel, and Atezolizumab in IMpassion Trials

Lisa A. Carey, MD, of the University of North Carolina, discusses phase III results from two IMpassion trials, 130 and 131, which explored, respectively, atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast...

solid tumors
immunotherapy

First-in-Class Human IgG4 Monoclonal Antibody Shows Activity Alone and Combined With Pembrolizumab in Advanced Solid Tumors

MK-4830—a novel, first-in-class human IgG4 monoclonal antibody targeting the myeloid-specific anti–immunoglobulin-like transcript 4 (ILT4) receptor—administered either as a single agent or in combination with pembrolizumab was well tolerated and showed activity in heavily pretreated patients with...

kidney cancer
genomics/genetics

Is ctDNA Effective in Detecting Genomic Alterations in Patients With Metastatic Kidney Cancer?

Circulating tumor DNA (ctDNA) analysis is a minimally invasive genomic assessment tool utilizing targeted next-generation sequencing of peripheral blood. At the ESMO Virtual Congress 2020, Zengin et al reported genomic results from a large cohort of patients with metastatic renal cell carcinoma...

Advertisement

Advertisement



Advertisement